Alzheimer's disease & dementia

Biogen CEO: 'Major bottleneck' still limits Alzheimer's drug

A new Alzheimer's drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, extending a slow debut complicated by coverage questions and doctor concerns.

Other

Johnson & Johnson announces new CEO

Alex Gorsky will step down as chief executive of Johnson & Johnson in January, ceding the role to longtime company executive Joaquin Duato, the health care giant announced Thursday.

Diseases, Conditions, Syndromes

Doctors: Execution drugs could help COVID-19 patients

Secrecy surrounding executions could hinder efforts by a group of medical professionals who are asking the nation's death penalty states for medications used in lethal injections so that they can go to coronavirus patients ...

page 1 from 3